The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study.

BACKGROUND: AQ4N (1,4-bis[[2-(dimethylamino)ethyl] amino]-5,8-dihydroxyanthracene-9, 10-dione bis-N-oxide dihydrochloride) is a prodrug which is selectively activated within hypoxic tissues to AQ4, a topoisomerase II inhibitor and DNA intercalator. PATIENTS AND METHODS: In the phase I study, 22 pati...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Steward, W, Middleton, M, Benghiat, A, Loadman, P, Hayward, C, Waller, S, Ford, S, Halbert, G, Patterson, L, Talbot, D
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: 2007